The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia
Abstract Neointima hyperplasia is a crucial component of restenosis after coronary angioplasty. We have hypothesized that enhanced generation of platelet-derived thromboxane (TX)A2 in response to vascular damage plays a critical role in neointimal hyperplasia and that antiplatelet agents may mitigat...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e6a515e9c8494e3e985c043ce7cad9e0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e6a515e9c8494e3e985c043ce7cad9e0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e6a515e9c8494e3e985c043ce7cad9e02021-12-02T15:11:51ZThe antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia10.1038/s41598-020-77934-x2045-2322https://doaj.org/article/e6a515e9c8494e3e985c043ce7cad9e02020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-77934-xhttps://doaj.org/toc/2045-2322Abstract Neointima hyperplasia is a crucial component of restenosis after coronary angioplasty. We have hypothesized that enhanced generation of platelet-derived thromboxane (TX)A2 in response to vascular damage plays a critical role in neointimal hyperplasia and that antiplatelet agents may mitigate it. In cocultures of human platelets and coronary artery smooth muscle cells (CASMC), we found that platelets induced morphologic changes and enhanced the migration of CASMC. The exposure of platelets to Aspirin [an inhibitor of cyclooxygenase (COX)-1] reduced the generation of TXA2 and prevented the morphological and functional changes induced by platelets in CASMC. Platelet-derived TXA2 induced COX-2 and enhanced prostaglandin (PG)E2 biosynthesis in CASMC, a known mechanism promoting neointimal hyperplasia. COX-2 induction was prevented by different antiplatelet agents, i.e., Aspirin, the TP antagonist SQ29,548, or Revacept (a dimeric soluble GPVI-Fc fusion protein). The administration of the novel antiplatelet agent Revacept to C57BL/6 mice, beginning three days before femoral artery denudation, and continuing up to seven days after injury, prevented the increase of the systemic biosynthesis di TXA2 and reduced femoral artery intima-to-media area and the levels of markers of cell proliferation and macrophage infiltration. Revacept might serve as a therapeutic agent for percutaneous coronary angioplasty and stent implantation.Sara AlbertiQianqian ZhangIlaria D’AgostinoAnnalisa BrunoStefania TacconelliAnnalisa ContursiSimone GuarnieriMelania DovizioLorenza FalconePatrizia BalleriniGötz MünchYing YuPaola PatrignaniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-13 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Sara Alberti Qianqian Zhang Ilaria D’Agostino Annalisa Bruno Stefania Tacconelli Annalisa Contursi Simone Guarnieri Melania Dovizio Lorenza Falcone Patrizia Ballerini Götz Münch Ying Yu Paola Patrignani The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia |
| description |
Abstract Neointima hyperplasia is a crucial component of restenosis after coronary angioplasty. We have hypothesized that enhanced generation of platelet-derived thromboxane (TX)A2 in response to vascular damage plays a critical role in neointimal hyperplasia and that antiplatelet agents may mitigate it. In cocultures of human platelets and coronary artery smooth muscle cells (CASMC), we found that platelets induced morphologic changes and enhanced the migration of CASMC. The exposure of platelets to Aspirin [an inhibitor of cyclooxygenase (COX)-1] reduced the generation of TXA2 and prevented the morphological and functional changes induced by platelets in CASMC. Platelet-derived TXA2 induced COX-2 and enhanced prostaglandin (PG)E2 biosynthesis in CASMC, a known mechanism promoting neointimal hyperplasia. COX-2 induction was prevented by different antiplatelet agents, i.e., Aspirin, the TP antagonist SQ29,548, or Revacept (a dimeric soluble GPVI-Fc fusion protein). The administration of the novel antiplatelet agent Revacept to C57BL/6 mice, beginning three days before femoral artery denudation, and continuing up to seven days after injury, prevented the increase of the systemic biosynthesis di TXA2 and reduced femoral artery intima-to-media area and the levels of markers of cell proliferation and macrophage infiltration. Revacept might serve as a therapeutic agent for percutaneous coronary angioplasty and stent implantation. |
| format |
article |
| author |
Sara Alberti Qianqian Zhang Ilaria D’Agostino Annalisa Bruno Stefania Tacconelli Annalisa Contursi Simone Guarnieri Melania Dovizio Lorenza Falcone Patrizia Ballerini Götz Münch Ying Yu Paola Patrignani |
| author_facet |
Sara Alberti Qianqian Zhang Ilaria D’Agostino Annalisa Bruno Stefania Tacconelli Annalisa Contursi Simone Guarnieri Melania Dovizio Lorenza Falcone Patrizia Ballerini Götz Münch Ying Yu Paola Patrignani |
| author_sort |
Sara Alberti |
| title |
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia |
| title_short |
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia |
| title_full |
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia |
| title_fullStr |
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia |
| title_full_unstemmed |
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia |
| title_sort |
antiplatelet agent revacept prevents the increase of systemic thromboxane a2 biosynthesis and neointima hyperplasia |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/e6a515e9c8494e3e985c043ce7cad9e0 |
| work_keys_str_mv |
AT saraalberti theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT qianqianzhang theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT ilariadagostino theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT annalisabruno theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT stefaniatacconelli theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT annalisacontursi theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT simoneguarnieri theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT melaniadovizio theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT lorenzafalcone theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT patriziaballerini theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT gotzmunch theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT yingyu theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT paolapatrignani theantiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT saraalberti antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT qianqianzhang antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT ilariadagostino antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT annalisabruno antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT stefaniatacconelli antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT annalisacontursi antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT simoneguarnieri antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT melaniadovizio antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT lorenzafalcone antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT patriziaballerini antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT gotzmunch antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT yingyu antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia AT paolapatrignani antiplateletagentrevaceptpreventstheincreaseofsystemicthromboxanea2biosynthesisandneointimahyperplasia |
| _version_ |
1718387665921900544 |